Table 1 Clinical trials targeting survivin in cancer

  YM155 (survivin suppressor) together with Paclitaxel and carboplatin

Solid tumors and advanced non-small cell lung carcinoma

I/II

NCT01100931

  Terameprocol (EM1421), inhibitor of survivin and cdc2 (cyclin-dependent kinase-1) in continuous intravenous infusion

Refractory Solid tumors

I

NCT00664586

  EZN-3042, a locked nucleic acid antisense oligonucleotide

Acute Lymphoblastic Leukemia

I

NCT01186328

  Terameprocol (EM-1421), inhibitor of survivin and cdc2 (cyclin-dependent kinase-1)

Leukemia

I

NCT00664677

  EZN-3042, a survivin-targeted mRNA antagonist, alone or in combination with standard chemotherapy

Acute Lymphoblastic Leukemia

I

NCT01186328

  LY2181308, an antisense oligonucleotid, targeted against survivin mRNA in combination with idarubicin and cytarabine

Acute Myeloid Leukemia

II

NCT00620321

  Dendritic cell vaccine (mRNA from PSA, PAP, survivin and hTERT) plus docetaxel or docetaxel alone

Prostate Cancer (castration resistant and metastatic)

II

NCT01446731

  Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion

Melanoma

I/II

NCT00961844

  Drug: Temozolomide

  Procure®, denditric cells loaded with Survivin-peptide and Telomerase mRNA

Ovarian Cancer

I

NCT01456065

  Dendritic cell loaded with amplified ovarian cancer stem cell mRNA, hTERT/survivin mRNA

Ovarian Cancer

I/II

NCT01334047

  Cell therapy based on dendritic cells transfected with Survivin, hTERT and p53 mRNA

Metastatic breast cancer

I

NCT00978913

Malignant melanoma

  TAA-SPECIFIC CTLs targeting survivin, PRAME, NY-ESO-1, MAGEA4 and SSX

Solid Tumors (TACTASOM)

I

NCT02239861

  Treatment with autologous dendritic cells transfected with Survivin, MelanA and MAGE-A3 mRNA or loaded with MAGE-A3, MelanA and Survivin

Melanoma

I/II

NCT00074230

  Cell therapy with cytotoxic T lymphocytes exposed to tumor associated antigens: NY-ESO-1, MAGEA4, PRAME, Survivin and SSX.

Hodgkin or Non-Hodgkin Lymphoma

I

NCT01333046

  TAA-CTLs may be generated from donors or recipients and will be tested for specificity against 4 tumor antigens commonly found in hematological malignancies (WT1, PRAME, SURVIVIN, and MAGE-A3).

I

NCT02203903

Hematological

Malignancies

  Dendritic cell vaccine (MUC-1 and survivin) in combination with cytokine-induced killer cells

Soft Tissue Sarcoma

I/II

NCT01898663

  Dendritic cell vaccine (MUC-1 and survivin) in combination with cytokine-induced killer cells

Renal Cell Carcinoma

I/II

NCT01924156

  Autologous dendritic cell vaccine (peptides from survivin and telomerase)

Renal Cell Carcinoma

I/II

NCT00197860

  Multiple antigen specific cellular therapy: autologous T cytotoxic cells induced by dendritic cells (loaded with p53, her2, survivin and a total of 17 antigens)

Hepatocellular Carcinoma

I/II

NCT02026362

  Vaccine therapy (p53, survivin and telomerase) with autologous dendritic cells in combination with adjuvant cytokines

Advanced Melanoma

I/II

NCT00197912

  Multiple tumor-associated antigen (TAA)-specific T cells (against WT1, PRAME and survivin) from donors

Acute Lymphoblastic Leukemia

I

NCT02475707

  Multiple tumor-associated antigen (TAA)-specific T cells (against WT1, NY-ESO-1, PRAME and survivin) from donors

Acute Lymphoblastic Leukemia/Myelodisplasic Syndrome

I

NCT02494167

  Multiple tumor-associated antigen (TAA)-specific cytotoxic T cells (against NY-ESO-1, IMAGEA4, PRAME, SSX and survivin) from donors

Multiple Myeloma

I

NCT02291848

  Survivin peptide vaccination in combination with sargramostin

Malignant Glioma

I

NCT01250470

  Vaccination with DPX-Survivin in combination with low doses of cyclophosphamide (The peptide antigens targeting survivin)

Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

I/II)

NCT01416038

  hTERT/survivin/CMV multipeptide vaccine

Breast Cancer

Not provided

NCT01660529

  Multipeptide vaccination including survivin-peptide

Multiple Myeloma

I/II

NCT00499577

  SurVaxM Vaccine (survivin-peptide vaccine) in combination with temozolamide

Glioblastoma

II

NCT02455557

  Peptide vaccine (IDO/survivine peptide) as enhancer of temozolomide chemotherapy

Metastatic Melanoma

II

NCT01543464

  Vaccine therapy (MART1 analog, gp100 and survivin) and GM-CSF with or without Aldesleukin

Melanoma

I

NCT00470015

  Vaccine therapy (survivin) in patients receiving lenalidomide

Multiple Myeloma

I

NCT02334865

  hTERT tumor vaccine (peptides from telomerase, survivin and cytopeptide) in combination with autologous T cell infusion

Multiple Myeloma

I/II

NCT00834665

  Immunotherapeutic vaccine DPX-Survivac (targeting survivin) in combination with cyclophosphamide

Diffuse Large B-Cell Lymphoma

II

NCT02323230

  Survivin and telomerase peptide vaccination in combination with Daclizumab and Prevnar

Advanced Breast cancer

I

NCT00573495

  Survivin peptide vaccination

Advanced Melanoma, pancreatic, colon and cervical cancer

I/II

NCT00108875